Takeda Highlights Pioglitazone Fracture Risk In "Dear Healthcare Provider" Letter
This article was originally published in PharmAsia News
Executive Summary
Takeda is notifying healthcare providers there is an increased risk of fracture in women taking pioglitazone drugs for treatment of type 2 diabetes, according to a March 9 FDA MedWatch alert. The alert marks the second time in several weeks the agency has cautioned doctors regarding thiazolidinediones (TZDs) and fracture risk
You may also be interested in...
GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women
FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).